welcome to oneEDSvoice
- a positively charged Ehlers Danlos Syndrome community.- join today!
- login
Acer Therapeutics Obtains Exclusive License to Celiprolol Pivotal Clinical Data from AP-HP
“We have studied celiprolol for nearly two decades in vEDS patients and this is the only drug ever to demonstrate a clinical benefit in a randomized, controlled clinical study,” said Pierre Boutouyrie M.D., Ph.D., co-director of the clinical pharmacology service at the Georges-Pompidou European Hospital AP-HP and Principal Investigator for the celiprolol study. “Having established celiprolol as a standard of care in France for vEDS patients, we are excited to partner with Acer to help bring celiprolol to members of the U.S. patient community who are suffering from this devastating, life-threatening disease.”
expertly curated content related to this topic
-
Neil Schechter, MDDr. Neil Schechter currently directs the...
-
Joint Capsule Collagen. Analysis by the Study of Intra-articular Pressure during Joint Distension. Measurements in t...The joint capsule contains both elastic ...
-
Fatigue is a Frequent and Clinically Relevant Problem in Ehlers-Danlos SyndromeOBJECTIVES: Ehlers-Danlos Syndrome (EDS...
-
Mayo ClinicMayo Clinic is a nonprofit organization ...
-
Cynthia Allen, GCFP, STMICynthia Allen is a movement specialist t...
-
Professor Jaime F. Bravo, MDProfessor Jaime F. Bravo , MD is a speci...
-
Forest Tennant, MD, DrPHForest Tennant is an American physicia...
